COMMITS-CAN V0.1
Research type
Research Study
Full title
Continuous glucose monitoring for improving clinical outcome and quality of life in patients with diabetes and cancer
IRAS ID
296415
Contact name
Ramzi A Ajjan
Contact email
Sponsor organisation
University of Leeds
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
One in four people with cancer also have diabetes, the majority have type 2 diabetes. Individuals with diabetes are thought to have a lower chance of successfully completing the treatment which is planned for their cancer, but the reasons for this are not fully understood.
It is thought that chemotherapy in particular might affect blood sugar levels, making it higher or lower in some people, and that this may lead to complications. What is not known is how big this effect is and how long it lasts. This study wants to use a device which continuously monitors blood sugar in people with type 2 diabetes who are having chemotherapy to see whether more detailed monitoring of blood sugar can help more people complete the treatment which is planned for them.REC name
East Midlands - Nottingham 2 Research Ethics Committee
REC reference
23/EM/0250
Date of REC Opinion
14 Dec 2023
REC opinion
Further Information Favourable Opinion